# Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)

> **NCT06903156** · PHASE2 · COMPLETED · sponsor: **Pharmasoft** · enrollment: 102 (actual)

## Conditions studied

- Primary Open-Angle Glaucoma (POAG)

## Interventions

- **DRUG:** Mexidol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06903156
- **Lead sponsor:** Pharmasoft
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-15
- **Primary completion:** 2023-09-07
- **Final completion:** 2023-09-07
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06903156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06903156, "Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06903156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*